10x Genomics Inc

For the period ended Dec 31, 2024. Filed Feb 13, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Feb 13, 2025

TXG$65.05+9.7%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets

(In thousands, except share and per share data)

	December 31,
	2024	2023
Assets
Current assets:
Cash and cash equivalents	$344,067	$359,284
Marketable securities	49,335	29,411
Accounts receivable, net	87,862	114,832
Inventory	83,107	73,706
Prepaid expenses and other current assets	20,016	18,789
Total current assets	584,387	596,022
Property and equipment, net	252,648	279,571
Operating lease right-of-use assets	57,290	65,361
Goodwill	4,511	4,511
Intangible assets, net	15,671	16,616
Other noncurrent assets	4,129	3,062
Total assets	$918,636	$965,143
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable	$12,909	$15,738
Accrued compensation and related benefits	33,615	30,105
Accrued expenses and other current liabilities	41,165	56,648
Deferred revenue	20,658	13,150
Operating lease liabilities	9,286	11,521
Total current liabilities	117,633	127,162
Operating lease liabilities, noncurrent	73,327	83,849
Deferred revenue, noncurrent	12,513	8,814
Other noncurrent liabilities	5,029	4,275
Total liabilities	208,502	224,100
Commitments and contingencies (Note 7)
Stockholders' equity:
Preferred stock, $0.00001 par value; 100,000,000 shares authorized, no shares issued or outstanding as of December 31, 2024 and 2023	—	—
Common stock, $0.00001 par value; 1,100,000,000 shares authorized (Class A 1,000,000,000, Class B 100,000,000); 122,291,837 (Class A 108,235,004, Class B 14,056,833) and 119,095,362 (Class A 105,038,529, Class B 14,056,833) shares issued and outstanding as of December 31, 2024 and 2023, respectively	2	2
Additional paid-in capital	2,177,672	2,025,890
Accumulated deficit	(1,467,047)	(1,284,420)
Accumulated other comprehensive loss	(493)	(429)
Total stockholders’ equity	710,134	741,043
Total liabilities and stockholders’ equity	$918,636	$965,143

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.